CDH5 and breast carcinoma: As the majority of newly diagnosed breast cancers are ER positive (Yasui and Potter, 1999; Anderson et al, 2002; Piccart-Gebhart, 2011) it is therefore encouraging that the CDH5:HPA ratio was able to discriminate ER-positive breast cancer patients with different clinical outcomes.